Interleukin-2 (IL-2) Mutein Therapies Market Outlook Highlights The Next Major Growth Opportunities
Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.
Interleukin-2 (IL-2) Mutein Therapies Market Expected To Reach $1.43 Billion By 2030 At 14.4% CAGR
The market for interleukin-2 (il-2) mutein therapies has experienced rapid expansion in its size over recent years. This market is projected to expand from $0.73 billion in 2025 to $0.84 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 14.1%. The historical growth of this market can be linked to several factors, including strides in cytokine engineering techniques, a deeper comprehension of immune signaling pathways, initial clinical triumphs of altered IL-2 therapies, increased funding in immuno-oncology research, and the rising occurrence of immune-related ailments.
The interleukin-2 (il-2) mutein therapies market is set for significant expansion in the upcoming years. It is projected to reach $1.43 billion by 2030, progressing at a compound annual growth rate (CAGR) of 14.4%. This anticipated growth is influenced by the broadening of personalized immunotherapy approaches, an uptick in clinical trial activities for next-generation cytokines, an increasing demand for safer immune modulators, robust regulatory backing for innovative biologics, and a surge in partnerships between biotechnology and pharmaceutical companies. Noteworthy trends during this period include the accelerated development of receptor-biased il-2 muteins, a concentrated effort on achieving reduced cytokine toxicity profiles, the growing application of combination immunotherapy regimens, the expansion of precision immune modulation techniques, and enhanced clinical pipeline activities for autoimmune and oncology indications.
Download A Free Sample Report For Comprehensive Market Insights:
Interleukin-2 (IL-2) Mutein Therapies Market Growth Drivers: What Factors Are Accelerating Expansion?
Growing demand for targeted immunotherapies is projected to fuel expansion within the interleukin-2 (IL-2) mutein therapies market. These treatments aim to adjust the immune system, enabling it to specifically target cancer cells and minimize harm to healthy tissues. The need for such therapies is increasing because healthcare professionals and researchers are searching for safer, more potent options compared to traditional chemotherapy and radiation, which frequently involve considerable toxicity and a lack of precision. IL-2 mutein therapies contribute to the progress of targeted immunotherapies by employing modified versions of interleukin-2 that specifically activate immune effector cells crucial for anti-tumor actions, simultaneously reducing the stimulation of pathways linked to widespread toxicity. As an example, the Cancer Research Institute, a US-based non-profit organization, reported in April 2025 that the FDA approved 17 new targeted immunotherapy agents in 2024. This expanded the available options for immune-based cancer treatment and broadened the number of patients eligible for these therapies. Consequently, the heightened requirement for targeted immunotherapies is accelerating the expansion of the interleukin-2 (IL-2) mutein therapies market.
Interleukin-2 (IL-2) Mutein Therapies Market Segment Analysis Highlighting Growth Areas
The interleukin-2 (il-2) mutein therapies market covered in this report is segmented –
1) By Product Type: Monotherapy; Combination Therapy
2) By Route Of Administration: Intravenous; Subcutaneous; Other Route Of Administrations
3) By Application: Cancer; Autoimmune Diseases; Infectious Diseases; Other Applications
4) By End User: Hospitals; Specialty Clinics; Research Institutes; Other End Users
Subsegments:
1) By Monotherapy: Single Agent Interleukin Two Mutein Therapy; Standalone Cytokine Based Immunotherapy; Targeted Immune Modulation Therapy
2) By Combination Therapy: Interleukin Two Mutein With Immune Checkpoint Inhibitors; Interleukin Two Mutein With Chemotherapy; Interleukin Two Mutein With Targeted Biologic Therapies; Interleukin Two Mutein With Cell Based Therapies
Interleukin-2 (IL-2) Mutein Therapies Market Trends: What Is Shaping Future Industry Growth?
Leading firms within the interleukin-2 (IL-2) mutein therapies market are directing more attention towards technological progress in cytokine-based immunotherapy, specifically concerning methods like selective regulatory T-cell (Treg) activation achieved via engineered IL-2 muteins. This process of selective regulatory T-cell activation, facilitated by engineered IL-2 muteins, entails employing genetically altered IL-2 proteins crafted to primarily activate Tregs while simultaneously curbing the stimulation of effector immune cells. As an illustration, in December 2023, Almirall S.A., a pharmaceutical company based in Spain, commenced the initial Phase I clinical investigation of its engineered IL-2 mutein fusion protein, ALM223. This study aims to assess its safety, pharmacokinetics, immunogenicity, and pharmacodynamics within the context of autoimmune diseases. This particular candidate compound incorporates selective Treg activation, an adapted Fc fusion for enhanced molecular stability, and an engineered cytokine backbone designed to optimize immune modulation. Although these technological advancements underscore the potential of IL-2 muteins for achieving precise immunomodulation and wider applicability in autoimmune conditions, their clinical effectiveness and long-term safety characteristics still require confirmation through current and forthcoming trials.
Interleukin-2 (IL-2) Mutein Therapies Market Leading Companies: Who Holds Significant Market Presence?
Major companies operating in the interleukin-2 (il-2) mutein therapies market are Merck & Co. Inc., Sanofi S.A., Roche Holding AG, Bristol-Myers Squibb, Amgen Inc., Lonza Group AG, Alkermes plc, BioNTech SE, Xencor Inc., Innovent Biologics Inc., Ascendis Pharma A/S, ShanghAI Junshi Biosciences Co. Ltd., Mural Oncology Inc., ProBioGen AG, Werewolf Therapeutics Ltd., Philogen S.p.A., Cue Biopharma Inc., Medicenna Therapeutics Corp., Bright Peak Therapeutics Inc., Iovance Biotherapeutics Inc.
Access The Complete Interleukin-2 (IL-2) Mutein Therapies Market Report:
Interleukin-2 (IL-2) Mutein Therapies Market Leading Geography: Which Region Generates The Most Revenue?
North America was the largest region in the interleukin 2 (IL-2) mutein therapies market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the interleukin-2 (il-2) mutein therapies market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
